drugset / Trial / NCT00219544

Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NCT00219544

Phase 3 Completed 158 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).

Timeline

Start
2005-11
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 300 mg
Subject Pregabalin Small molecule 600 mg

Indications